Tags · Evidence

randomised trial

Randomised controlled trial evidence.

174 topics 62 solved Group: Evidence

174 topics · page 6 of 6

Topic	Participants	Replies	Views	Activity
SNAC and the mechanism of oral peptide absorption — the long version Compounds › Oral incretins oral semaglutide randomised trial orforglipron SNAC and the mechanism of oral peptide absorption — the long version Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited in…	+32	36	6.8k	16mo
Retatrutide's phase 2 heart-rate signal and how to think about it — the long version Compounds › Retatrutide effect size randomised trial TRIUMPH programme Solved Retatrutide's phase 2 heart-rate signal and how to think about it — the long version Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med…		2	103	17mo
SNAC and the mechanism of oral peptide absorption Compounds › Oral incretins orforglipron randomised trial PIONEER programme oral semaglutide On the subject in the title: SNAC and the mechanism of oral peptide absorption Working notes rather than a conclusion. Comparing SELECT ( N Engl J Med , 2023) with SURPASS-4 ( Lancet , 2021) and finding the…	+13	17	14k	17mo
[2026 update] Journal club: SURPASS-2 and the semaglutide 1 mg comparator Evidence › Journal club estimand randomised trial number needed to treat effect size Journal club: SURPASS-2 and the semaglutide 1 mg comparator Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURPASS-4 ( Lancet , 2021). Please read it before…	+126	138	31k	17mo
Semaglutide in people without diabetes: what the evidence base looks like Compounds › Semaglutide semaglutide effect size STEP programme randomised trial Semaglutide in people without diabetes: what the evidence base looks like Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SUSTAIN 6 ( N Engl J Med , 2016).…	+2	6	18k	17mo
Amylin and gastric emptying: overlapping mechanisms with incretins Compounds › Cagrilintide & amylin analogues cagrisema amylin analogues randomised trial On the subject in the title: Amylin and gastric emptying: overlapping mechanisms with incretins Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before posting;…		2	50k	17mo
Reading a supplementary appendix and finding the interesting part Evidence › Trials open label discontinuation & dropout intention to treat estimand Reading a supplementary appendix and finding the interesting part — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do…	+87	92	1.1k	17mo
Second pass at: Historical amylin analogues and what happened to them Compounds › Cagrilintide & amylin analogues amylin analogues effect size cagrilintide cagrisema Closed Second pass at: Historical amylin analogues and what happened to them — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim…	+15	19	22k	18mo
SURPASS-2 and the comparator dose question that will not go away Compounds › Tirzepatide SURPASS programme randomised trial effect size SURMOUNT programme SURPASS-2 and the comparator dose question that will not go away — setting out what I have, and where I think it stops being reliable. Session topic: FLOW ( N Engl J Med , 2024). Please read it before…	+101	111	1.5k	18mo
Dose numbers for oral formulations are not comparable to injectable ones — a second dataset Compounds › Oral incretins randomised trial orforglipron PIONEER programme Dose numbers for oral formulations are not comparable to injectable ones — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SUSTAIN 6 ( N Engl…	+48	52	59k	18mo
Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide Compounds › Semaglutide effect size type 2 diabetes randomised trial Solved Posting this under the heading it deserves: Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide Everything below is what sits behind that. I have seen SURMOUNT-4 ( JAMA ,…	+72	77	7.2k	19mo
Oral semaglutide bioavailability and its variability between people — a second dataset Compounds › Oral incretins randomised trial PIONEER programme SOUL trial Closed Oral semaglutide bioavailability and its variability between people — a second dataset — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support…	+141	154	47k	19mo
Molecular mass of semaglutide and why the figure differs between sources — does this still hold? Compounds › Semaglutide effect size type 2 diabetes STEP programme SELECT trial Solved Closed Molecular mass of semaglutide and why the figure differs between sources — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SURPASS-2 (…	+94	102	14k	19mo
Follow-up: Semaglutide versus liraglutide head to head: reading STEP 8 carefully Compounds › Semaglutide effect size randomised trial SELECT trial STEP programme Semaglutide versus liraglutide head to head: reading STEP 8 carefully — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim…	+1	5	11k	20mo
Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold? Compounds › Semaglutide randomised trial type 2 diabetes STEP programme effect size Solved Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SCALE ( N…	+58	62	49k	20mo
[2026 update] Comparing tirzepatide and semaglutide is harder than the tables suggest Compounds › Tirzepatide effect size SURMOUNT programme tirzepatide randomised trial Comparing tirzepatide and semaglutide is harder than the tables suggest Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURPASS-4 ( Lancet , 2021) with SURMOUNT-1…		2	23k	21mo
Journal club: SURPASS-2 and the semaglutide 1 mg comparator Evidence › Journal club estimand effect size risk of bias journal club Solved On the subject in the title: Journal club: SURPASS-2 and the semaglutide 1 mg comparator Working notes rather than a conclusion. Session topic: SELECT ( N Engl J Med , 2023). Please read it before posting;…	+71	76	52k	21mo
Hepatic effects of glucagon receptor agonism: the mechanistic worry Compounds › Retatrutide TRIUMPH programme effect size preprint randomised trial Solved Posting this under the heading it deserves: Hepatic effects of glucagon receptor agonism: the mechanistic worry Everything below is what sits behind that. Session topic: SURMOUNT-4 ( JAMA , 2024). Please read…	+51	56	700	22mo
The C-cell question: rodent findings and their human context — what changed since Compounds › Semaglutide effect size SELECT trial randomised trial type 2 diabetes Closed The C-cell question: rodent findings and their human context — what changed since — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support…	+61	65	1.3k	22mo
About the Retatrutide category Compounds › Retatrutide retatrutide TRIUMPH programme randomised trial Pinned Wiki Triple GIP/GLP-1/glucagon receptor agonist. Phase 2 data, TRIUMPH programme, and cautious practical discussion. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit…		4	12k	2y
The most common factual error about semaglutide on the internet Compounds › Semaglutide STEP programme randomised trial type 2 diabetes effect size On the subject in the title: The most common factual error about semaglutide on the internet Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before posting; the…		2	49k	2y
Second pass at: Journal club: LEADER as the historical anchor Evidence › Journal club randomised trial journal club effect size estimand Posting this under the heading it deserves: Second pass at: Journal club: LEADER as the historical anchor Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with SURPASS-2 ( N…	+75	81	2k	2y
Second pass at: Retatrutide dose escalation in the published trials Compounds › Retatrutide retatrutide randomised trial preprint Under review Second pass at: Retatrutide dose escalation in the published trials — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a claim…	+115	125	30k	2y
Journal club: FLOW and the renal composite, component by component Evidence › Journal club randomised trial estimand risk of bias On the subject in the title: Journal club: FLOW and the renal composite, component by component Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before posting;…	+84	91	18k	2y